Regeneron tops Q3 revenue expectations with $5.12 billion in revenue
FROM THE WIRE · FINANCE.YAHOO.COM
The top 5 analyst questions from Regeneron's Q3 earnings call Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street's revenue and profit expectations. Management credited growth to…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishResults above estimates for a large biotech company, with focus on its core products.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue was $5.12 billion versus an estimate of $4.60 billion.
- 02Dupixent, Eylea HD and Libtayo all reached new all-time sales highs.
- 03The expanded collaboration with Sanofi contributed to growth.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Regeneron Pharmaceuticals, Inc.959.72 USD-1.14%today +3.43%Positive Sanofi44.94 USD+0.26%today +1.35%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets